Novo Nordisk shares fall
Novo Nordisk cut its full-year earnings outlook after reporting weaker-than-expected quarterly sales of its popular weight-loss drug Wegovy, raising concerns among investors about growing competition from Eli Lilly. The results end a prolonged run of positive earnings news from Europe’s most valuable listed company.
ENTRADAS POPULARES
Spain’s vice-president Ribera blames floods on climate change
noviembre 22, 2024
Storm lashes northwestern US, killing two people
noviembre 22, 2024
Iceland volcano erupts for tenth time in three years
noviembre 22, 2024
A banana wrapped in duct tape sells for $6.2 million at auction
noviembre 22, 2024
TRANSMISIÓN EN VIVO